News Releases

ITA Partners Becomes eviti, Inc.

Home Home > News Releases > ITA Partners Becomes eviti, Inc.
| January 17, 2012 |

ITA Partners, Inc. announced that it has officially changed its company name to eviti, Inc. The new name reflects the company’s transformation to a health information technology business delivering web-based decision-support services to improve the quality of cancer care and reduce cost – beyond oncology pathways. eviti is the culmination of almost a decade of experience in oncology treatment intelligence, uniquely delivering value to all parties in the care process by ensuring quality care is prescribed from the start.

“Our customers have come to associate eviti with quality oncology treatment intelligence. In fact, payers using the eviti platform have seen the use of non-evidence-based, non plan-compliant care substantially decrease to less than 10% from historic levels between 32% and 41%,” said Eduardo Beruff, President and CEO, eviti, Inc. “This name change reflects eviti’s growing national prominence as evidenced by the 4,200 oncologists already registered to use the eviti platform.”

The eviti platform aligns physician, payer and patient priorities at the point of clinical prescribing to ensure the most appropriate, evidence-based oncology treatment is selected from the start. eviti, Inc.’s independent, non-proprietary digital oncology treatment library is one of the most comprehensive and current of its kind. It comprises over 1,100 of the most appropriate, proven treatment options and thousands of clinical trials, covering all modalities for more than 120 cancer types. eviti’s robust library is meticulously compiled from data from internationally recognized governmental and industry sources, and is maintained by expert oncologists, a world-class medical advisory board, and other medical informatics professionals.

eviti’s treatment knowledge base and patent-pending decision-support engine help oncologists select a treatment option that is both evidence-based and compliant with each patient’s insurance plan language at the moment of prescribing – without geographical boundaries. This transparent approach streamlines workflow and reimbursement, reduces variability in clinical care, and results in cost efficiencies to benefit all participants in the cancer treatment process and allow the best cancer care to be available everywhere. For more information, visit the company’s website at